Biora Therapeutics Announces Award-Winning Abstract to be Presented at American College of Gastroenterology Annual Scientific Meeting 2024
Rhea-AI Summary
Biora Therapeutics (Nasdaq: BIOR) announced an upcoming poster presentation at the American College of Gastroenterology (ACG) Annual Scientific Meeting in Philadelphia, October 25–30, 2024. The company's submission was awarded a Presidential Poster Award, a distinction given to less than 5% of accepted abstracts for high-quality, novel, and interesting research.
The poster presentation details are:
- Poster Number: P4275
- Session Date: October 29, 2024, 10:30 AM – 4:00 PM ET
- Presenting Author: Brian Feagan, MD, FRCPC
The research is embargoed until October 27, 2024, at 12:00 ET. Biora will make the poster available on their website at the time of presentation.
Positive
- Biora Therapeutics' abstract received a prestigious Presidential Poster Award, indicating high-quality research
- The company's research will be presented at a major industry event, potentially increasing visibility and credibility
Negative
- None.
News Market Reaction – BIOR
On the day this news was published, BIOR declined 2.39%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced an upcoming poster presentation at the American College of Gastroenterology (ACG) Annual Scientific Meeting, which will be held in Philadelphia, October 25–30, 2024.
Biora’s submission was awarded a Presidential Poster Award by the ACG Abstract Selection Committee. Each year less than
| Poster Number: | P4275 |
| Session Date: | October 29, 2024 10:30 AM – 4:00 PM ET |
| Presenting Author: | Brian Feagan, MD, FRCPC |
All research presented at ACG 2024, including abstract titles, is strictly embargoed until Sunday, October 27 at 12:00 ET. A copy of the poster will be made available on the Biora Therapeutics website at the time of presentation.
About Biora Therapeutics
Biora Therapeutics is a clinical-stage biotech company developing two smart pill-based therapeutics platforms: the NaviCap™ platform for colon-targeted treatment of IBD, designed to improve patient outcomes through treatment at the site of disease in the gastrointestinal tract, and the BioJet™ platform for oral delivery of large molecules, designed to replace injection with needle-free, oral delivery for better management of chronic diseases.
For more information, visit bioratherapeutics.com or follow the company on LinkedIn or X.
Safe Harbor Statement or Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the progress and future expectations and goals of our research and development, preclinical and clinical trial activities, including those involving BT-600 and our NaviCap platform and model-based data projections for the BT-600 program, and partnering and collaboration efforts with third parties, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “envision,” “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “anticipate,” “forward,” “believe,” “design,” “estimate,” “predict,” “projects,” “projecting,” “potential,” “plan,” “goal(s),” “target,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks, uncertainties, and other factors include, among others, our ability to innovate in the field of therapeutics, our ability to make future FDA filings and initiate and execute clinical trials on expected timelines or at all, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our plans to research, develop, and commercialize new products, the unpredictable relationship between preclinical study results and clinical study results, our expectations regarding allowed patents or intended grants to result in issued or granted patents, our expectations regarding opportunities with current or future pharmaceutical collaborators or partners, our ability to raise sufficient capital to achieve our business objectives, our ability to maintain our listing on the Nasdaq Global Market, and those risks described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC) and other subsequent documents, including Quarterly Reports on Form 10-Q, that we file with the SEC.
Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.
Investor Contact
Chuck Padala
Managing Director, LifeSci Advisors
IR@bioratherapeutics.com
(646) 627-8390
Media Contact
Liz Robinson
CG Life
lrobinson@cglife.com
FAQ
When will Biora Therapeutics (BIOR) present their research at the ACG Annual Scientific Meeting 2024?
What award did Biora Therapeutics (BIOR) receive for their abstract submission to ACG 2024?
Who is presenting Biora Therapeutics' (BIOR) research at the ACG Annual Scientific Meeting 2024?
When will the embargo on Biora Therapeutics' (BIOR) research for ACG 2024 be lifted?
